Skip to main content
Indoco Remedies Ltd. logo

Indoco Remedies Ltd. — Investor Relations & Filings

Ticker · INDOCO ISIN · INE873D01024 LEI · 3358007XE9RRPHJA6U47 BSE.NS Manufacturing
Open in API
Filings indexed 774 across all filing types
Latest filing 2019-11-01 Regulatory Filings
Country IN India
Listing BSE.NS INDOCO

About Indoco Remedies Ltd.

https://www.indoco.com/

Indoco Remedies Ltd. is a fully integrated pharmaceutical company engaged in the research, development, manufacturing, and marketing of finished dosages and Active Pharmaceutical Ingredients (APIs). The company operates multiple manufacturing facilities equipped to produce various dosage forms, including tablets, capsules, injectables, ophthalmics, and topical preparations. Its therapeutic portfolio spans stomatologicals, anti-infectives, respiratory, cardiovascular, anti-diabetics, and pain management. Indoco maintains a significant global footprint, exporting products to over 55 countries, including highly regulated markets such as the United States and Europe. The organization is recognized for its strong research and development capabilities, focusing on complex generics and niche formulations. Key brands include Sensodent-K, Febrex Plus, and Cyclopam, reflecting its leadership in specific therapeutic segments.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release dated November 1, 2019, announcing the approval of an Abbreviated New Drug Application (ANDA) by the USFDA for a product from Indoco Remedies Ltd. It contains no financial statements, no detailed financial performance data, no regulatory certifications, or voting results. It is a corporate announcement about product approval and business development. The document length is 3010 characters, which is relatively short and typical for a press release. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is not a report publication announcement either, as it is not announcing the release of a report but rather a business event. The best fitting category is Regulatory Filings (RNS) as a general regulatory announcement about a significant business development that does not fit other specific categories.
2019-11-01 English
Updates
Regulatory Filings Classification · 95% confidence The document text is extremely short (464 characters) and appears to be an address or header related to stock exchanges (National Stock Exchange of India and BSE Limited). There is no substantive content, financial data, or report information. It does not contain any financial statements, management discussion, or regulatory details. Given the brevity and nature of the text, it is likely a regulatory announcement or a brief communication rather than a full report or detailed filing. According to the rules, such short documents that do not contain actual report content and appear to be formal communications should be classified as Regulatory Filings (RNS).
2019-10-31 English
Financial Result Updates
Regulatory Filings
2019-10-30 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Indoco Remedies Ltd.'s Clinical Research Organisation successfully cleared a USFDA inspection with zero 483s. It contains no financial data, no detailed report, no regulatory filing, or management discussion. It is a corporate announcement about an operational achievement rather than a financial or regulatory report. The document length is short (2861 characters) and it is clearly a press release. Therefore, it does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. The closest fitting category is Regulatory Filings (RNS) as a general regulatory announcement or corporate update that does not fit other specific categories.
2019-10-18 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the successful conclusion of a USFDA inspection at Indoco Remedies' Goa Plant II. It provides details about the inspection dates, observations, and the company's response plans. There are no financial statements, detailed financial data, or regulatory filings such as annual or quarterly reports. The document is informational and promotional in nature, typical of a press release rather than a formal regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is also not related to management changes, voting results, or capital updates. Given the content and length (2803 characters), this is best classified as a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories.
2019-10-16 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings
2019-10-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.